Xuechen Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xuechen Chen has a total of 352 co-authors. Here are the top co-authors by number of shared publications:
- Hermann Brenner
Cancer Prevention Graduate School, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
39 shared publications - Michael Hoffmeister
Division of Clinical Epidemiology of Early Cancer Detection, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
32 shared publications - Neil Murphy
Nutrition and Metabolism Branch, International Agency for Research on Cancer, Lyon, France
25 shared publications - Alicja Wolk
Unit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet , Stockholm
24 shared publications - Andrew T. Chan
Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
24 shared publications - David Timothy Bishop
Leeds Institute of Medical Research, University of Leeds, Leeds, UK
24 shared publications
Latest Publications
- Open Access
- 18 June 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Associations of genetic and non-genetic cardiovascular health metrics with coronary artery disease incidence in cancer survivors
Cardiovascular disease (CVD) is a leading threat to long-term health in cancer survivors. This study aimed to evaluate whether integrating genetic risk with the composite cardiovascular health metric, the Life's Essential 8 (LE8) score, can improve primary prevention and guide personalized survivorship care in this population. We conducted a retrospective cohort study including 21,751 cancer survivors and 87,004 matched non-cancer controls from the UK Biobank. For each participant, a LE8 score, encompassing eight CVD-related factors (diet, physical activity, nicotine exposure, sleep, body mass index, blood pressure, blood glucose, and non-high-density lipoprotein cholesterol), and a polygenic risk score (PRS) for coronary artery disease (CAD) were calculated. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for incident risk of CAD across LE8 (or individual LE8 components) and PRS levels and to examine their potential interactions. A higher LE8 score and a lower PRS were independently associated with reduced CAD risk in cancer survivors. Participants with a high LE8 score and low PRS had the lowest CAD risk (HR 0.22; 95% CI, 0.09 0.53) when compared with those with a low LE8 score and high PRS. Similar patterns were observed in matched controls who had a lower CAD incidence rate. Associations between optimal blood lipid levels (as defined in the LE8 score) seemed to be more pronounced in individuals with high PRS, although it did not reach statistical significance among cancer survivors (p for interaction with PRS = 0.14 and 0.011, respectively, in cancer survivors and matched controls). Subgroup analyses showed consistent associations between LE8 score and CAD risk in breast, prostate, colorectal, and malignant skin cancer survivors, but not in those with lymphoma or hematologic malignancies. Furthermore, the association between LE8 score and CAD risk was stronger 5-10 years after cancer diagnosis and among younger cancer survivors aged under 55 years. Both a higher LE8 score and lower PRS for CAD were independently associated with substantially reduced risk of incident CAD.
- 18 June 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessAssociations of genetic and non-genetic cardiovascular health metrics with coronary artery disease incidence in cancer survivors
Cardiovascular disease (CVD) is a leading threat to long-term health in cancer survivors. This study aimed to evaluate whether integrating genetic risk with the composite cardiovascular health metric, the Life's Essential 8 (LE8) score, can improve primary prevention and guide personalized survivorship care in this population. We conducted a retrospective cohort study including 21,751 cancer survivors and 87,004 matched non-cancer controls from the UK Biobank. For each participant, a LE8 score, encompassing eight CVD-related factors (diet, physical activity, nicotine exposure, sleep, body mass index, blood pressure, blood glucose, and non-high-density lipoprotein cholesterol), and a polygenic risk score (PRS) for coronary artery disease (CAD) were calculated. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for incident risk of CAD across LE8 (or individual LE8 components) and PRS levels and to examine their potential interactions. A higher LE8 score and a lower PRS were independently associated with reduced CAD risk in cancer survivors. Participants with a high LE8 score and low PRS had the lowest CAD risk (HR 0.22; 95% CI, 0.09 0.53) when compared with those with a low LE8 score and high PRS. Similar patterns were observed in matched controls who had a lower CAD incidence rate. Associations between optimal blood lipid levels (as defined in the LE8 score) seemed to be more pronounced in individuals with high PRS, although it did not reach statistical significance among cancer survivors (p for interaction with PRS = 0.14 and 0.011, respectively, in cancer survivors and matched controls). Subgroup analyses showed consistent associations between LE8 score and CAD risk in breast, prostate, colorectal, and malignant skin cancer survivors, but not in those with lymphoma or hematologic malignancies. Furthermore, the association between LE8 score and CAD risk was stronger 5-10 years after cancer diagnosis and among younger cancer survivors aged under 55 years. Both a higher LE8 score and lower PRS for CAD were independently associated with substantially reduced risk of incident CAD.
- Open Access
- 1 January 2026
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 2026 (1)
BRAF/MEK Inhibitor–Associated Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis: A Systematic Review and an FDA Pharmacovigilance Database Study
Purpose: To evaluate the association between BRAFi/MEKi and Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) using disproportionality analysis and case reports. Methods: Case–non‐case reports (PubMed/Embase/Cochrane, up to June 2025) and FAERS data (Q1 2004–Q2 2025) were analyzed. Disproportionality signals were assessed using reporting odds ratio (ROR) and information component (IC). Included 154 SJS/TEN cases (17 from the literature, 139 from FAERS: SJS = 95, TEN = 44). Results: Vemurafenib (BRAFi) and cobimetinib (MEKi) showed significant SJS/TEN risk. Median onset age: 58 years; median latency: 13 days (SJS: 11, TEN: 22). Mortality: 14.0% (18/129 cases; SJS: 8.6%, TEN: 31.8%). Conclusion: BRAFi/MEKi are associated with SJS/TEN risk, necessitating vigilant monitoring and early intervention to mitigate severe outcomes.
- 1 January 2026
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 2026 (1)
Open AccessBRAF/MEK Inhibitor–Associated Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis: A Systematic Review and an FDA Pharmacovigilance Database Study
Purpose: To evaluate the association between BRAFi/MEKi and Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) using disproportionality analysis and case reports. Methods: Case–non‐case reports (PubMed/Embase/Cochrane, up to June 2025) and FAERS data (Q1 2004–Q2 2025) were analyzed. Disproportionality signals were assessed using reporting odds ratio (ROR) and information component (IC). Included 154 SJS/TEN cases (17 from the literature, 139 from FAERS: SJS = 95, TEN = 44). Results: Vemurafenib (BRAFi) and cobimetinib (MEKi) showed significant SJS/TEN risk. Median onset age: 58 years; median latency: 13 days (SJS: 11, TEN: 22). Mortality: 14.0% (18/129 cases; SJS: 8.6%, TEN: 31.8%). Conclusion: BRAFi/MEKi are associated with SJS/TEN risk, necessitating vigilant monitoring and early intervention to mitigate severe outcomes.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Genome-wide Interaction Study with Smoking for Colorectal Cancer Risk Identifies Novel Genetic Loci Related to Tumor Suppression, Inflammation, and Immune Response
This figure depicts the flowchart of the two-step interaction test.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Genome-wide Interaction Study with Smoking for Colorectal Cancer Risk Identifies Novel Genetic Loci Related to Tumor Suppression, Inflammation, and Immune Response
This figure depicts the flowchart of the two-step interaction test.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table S5 from Genome-wide Interaction Study with Smoking for Colorectal Cancer Risk Identifies Novel Genetic Loci Related to Tumor Suppression, Inflammation, and Immune Response
This file includes the association parameters (OR [95% CI]) for the identified SNPs with suggestive interaction term for smoking status by genotypes.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Genome-wide Interaction Study with Smoking for Colorectal Cancer Risk Identifies Novel Genetic Loci Related to Tumor Suppression, Inflammation, and Immune Response
This file includes the association parameters (OR [95% CI]) for the identified SNPs with suggestive interaction term for smoking status by genotypes.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table S8 from Genome-wide Interaction Study with Smoking for Colorectal Cancer Risk Identifies Novel Genetic Loci Related to Tumor Suppression, Inflammation, and Immune Response
This file includes the studies included in the analysis stratifing individuals by tumour features.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S8 from Genome-wide Interaction Study with Smoking for Colorectal Cancer Risk Identifies Novel Genetic Loci Related to Tumor Suppression, Inflammation, and Immune Response
This file includes the studies included in the analysis stratifing individuals by tumour features.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table S10 from Genome-wide Interaction Study with Smoking for Colorectal Cancer Risk Identifies Novel Genetic Loci Related to Tumor Suppression, Inflammation, and Immune Response
This file includes the expression imputation statistics and included SNPs from the elastin net models.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S10 from Genome-wide Interaction Study with Smoking for Colorectal Cancer Risk Identifies Novel Genetic Loci Related to Tumor Suppression, Inflammation, and Immune Response
This file includes the expression imputation statistics and included SNPs from the elastin net models.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from Genome-wide Interaction Study with Smoking for Colorectal Cancer Risk Identifies Novel Genetic Loci Related to Tumor Suppression, Inflammation, and Immune Response
This table includes the association parameters of smoking habits for colorectal cancer risk stratified by study type.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Genome-wide Interaction Study with Smoking for Colorectal Cancer Risk Identifies Novel Genetic Loci Related to Tumor Suppression, Inflammation, and Immune Response
This table includes the association parameters of smoking habits for colorectal cancer risk stratified by study type.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Genome-wide Interaction Study with Smoking for Colorectal Cancer Risk Identifies Novel Genetic Loci Related to Tumor Suppression, Inflammation, and Immune Response
This figure depicts the LocusZoom plots for SNPs interacting with smoking intensity for colorectal cancer risk.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Genome-wide Interaction Study with Smoking for Colorectal Cancer Risk Identifies Novel Genetic Loci Related to Tumor Suppression, Inflammation, and Immune Response
This figure depicts the LocusZoom plots for SNPs interacting with smoking intensity for colorectal cancer risk.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table S9 from Genome-wide Interaction Study with Smoking for Colorectal Cancer Risk Identifies Novel Genetic Loci Related to Tumor Suppression, Inflammation, and Immune Response
This file includes the association parameters of the interaction component (OR [95% CI]) for the identified SNPs for smoking habits stratified by tumor molecular markers.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S9 from Genome-wide Interaction Study with Smoking for Colorectal Cancer Risk Identifies Novel Genetic Loci Related to Tumor Suppression, Inflammation, and Immune Response
This file includes the association parameters of the interaction component (OR [95% CI]) for the identified SNPs for smoking habits stratified by tumor molecular markers.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from Genome-wide Interaction Study with Smoking for Colorectal Cancer Risk Identifies Novel Genetic Loci Related to Tumor Suppression, Inflammation, and Immune Response
This file includes the association parameters (OR [95% CI]) for the identified SNPs for smoking habits stratified by study type, sex and tumour site.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Genome-wide Interaction Study with Smoking for Colorectal Cancer Risk Identifies Novel Genetic Loci Related to Tumor Suppression, Inflammation, and Immune Response
This file includes the association parameters (OR [95% CI]) for the identified SNPs for smoking habits stratified by study type, sex and tumour site.